Among the populations most significantly affected by COVID-19 are the elderly and patients with preexisting medical conditions including diabetes, hypertension,
Study reveals cellular mechanism behind older adults' susceptibility to COVID-19
Home ยป
SARS-CoV-2 mutations alter dynamics of neutralizing antibodies
A new study published on the preprint server bioRxiv* describes how monoclonal antibodies raised against the severe acute respiratory syndrome
Rush to boosters sparks confusion, differing recommendations
When the Food and Drug Administration announced last week that a third dose of Moderna or Pfizer-BioNTech covid-19 vaccine may
Research associates prior encounter with seasonal coronavirus to milder COVID-19 symptoms
A study by Stanford University School of Medicine investigators hints that people with COVID-19 may experience milder symptoms if certain
New immunotherapy shows promising results in subgroup of people with type 1 diabetes
A clinical study led by Linköping University and financed by pharmaceuticals company Diamyd Medical has investigated whether immunotherapy against type
COVID-19 monoclonal antibodies reduce risk of hospitalization and death
Monoclonal antibodies, a COVID-19 treatment given early after coronavirus infection, cut the risk of hospitalization and death by 60% in
Biotinylated Heparan Sulfate Antibodies
AMSBIO has launched two new biotinylated formats of the 10E4 Heparan Sulfate antibody (high and low biotin) along with a
Broadly cross-reactive antibody to SARS-CoV-2 RBD with robust resistance to mutational escape
The current pandemic of coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has triggered an
New coronavirus variant with E484K mutation detected in Arizona
Arizona joins the ever-growing list of American states harboring a variant of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
SARS-CoV-2 variants with E484K mutation show mRNA vaccine-induced antibody evasion
A recent study by researchers in Switzerland found that the Pfizer-BioNTech mRNA vaccine had limited efficacy in identifying mutated receptor-binding